Most people with primary hyperparathyroidism have a normal or near-normal life expectancy, especially when the condition is treated with surgery. A large nationwide cohort study found that patients who underwent parathyroid surgery actually had slightly lower mortality than the general population. The picture is more complicated for secondary hyperparathyroidism, which develops alongside chronic kidney disease, but even there, treatment significantly improves survival. How long you live with this condition depends heavily on the type you have, whether you get treatment, and how much damage has already occurred by the time it’s caught.
Primary vs. Secondary: Two Different Conditions
Primary hyperparathyroidism happens when one or more of your parathyroid glands become overactive on their own, usually because of a benign tumor. This pumps too much parathyroid hormone into your blood, which raises calcium levels. It’s the most common form and is frequently discovered by accident on routine blood work.
Secondary hyperparathyroidism is a response to chronic kidney disease. When your kidneys can’t maintain proper calcium and phosphorus balance, your parathyroid glands work overtime to compensate. This form tends to be more serious because it’s layered on top of kidney failure, and the risks compound. The distinction matters because survival statistics differ substantially between the two.
Life Expectancy After Surgery
For primary hyperparathyroidism, surgery is essentially curative. A nationwide study tracking thousands of patients found that after parathyroid surgery, patients had a hazard ratio of 0.83 compared to the general population, meaning their risk of death was actually 17% lower than that of matched controls. This likely reflects the fact that surgical patients receive close medical follow-up, but the key takeaway is clear: treated primary hyperparathyroidism does not shorten your life.
Surgery also has an excellent track record for staying effective. A systematic review of over 30,000 patients found a recurrence rate of just 1.56%. At the five-year mark, only about 0.23% of patients saw the condition return, and at ten years, the rate was around 1%. For the vast majority of people, one operation resolves the problem permanently.
For secondary hyperparathyroidism in dialysis patients, surgery offers a different but still meaningful benefit. Dialysis patients who had parathyroid surgery had a 37% lower risk of death from any cause and a 33% lower risk of dying from cardiovascular disease compared to those managed without surgery. Median survival was 6.5 years for surgical patients versus 4.6 years for non-surgical controls. A broader meta-analysis confirmed these findings, showing that surgery cut the risk of death roughly in half (hazard ratio of 0.47) compared to medical treatment alone.
What Happens Without Treatment
Untreated primary hyperparathyroidism isn’t immediately dangerous in most people, but it does accumulate damage over time. In a study following 47 untreated patients, 34% developed a significant complication: peptic ulcers, declining kidney function, kidney stones, a dangerous calcium spike, or heart conduction problems. These complications don’t just affect quality of life. They can shorten it, particularly the cardiovascular and kidney effects.
Current guidelines recommend surgery for patients under 50, those whose calcium is more than 1 mg/dL above normal, anyone with bone density scores at or below -2.5, those with kidney stones, or patients whose kidney filtration rate drops below 60. Meeting any one of these criteria is enough to tip the balance toward surgery. For people who don’t meet any of these thresholds, monitoring is a reasonable option, but progression is common enough that many eventually qualify for surgery.
Cardiovascular Risks
The main way hyperparathyroidism threatens life expectancy is through the heart and blood vessels. Chronically elevated calcium promotes calcification of arteries, heart valves, and coronary vessels. This accelerates atherosclerosis, stiffens blood vessels, and thickens the heart’s left ventricle, forcing it to work harder.
Hospital data has linked primary hyperparathyroidism to significantly higher rates of stroke, coronary artery disease, atrial fibrillation, deep vein thrombosis, and pulmonary embolism. These associations held up even after accounting for other risk factors. High calcium also promotes blood clot formation and disrupts the inner lining of blood vessels, creating a cascade of problems that go well beyond what most people associate with a “calcium disorder.”
This cardiovascular burden is especially pronounced in secondary hyperparathyroidism. Cardiovascular disease is the leading cause of death in dialysis patients, and uncontrolled parathyroid hormone levels make it worse. The survival advantage of surgery in these patients comes largely from reducing cardiovascular deaths.
Bone Loss and Fracture Risk
Hyperparathyroidism pulls calcium from your bones, accelerating osteoporosis. This matters most for older adults, because fractures in this population carry real mortality risk. The one-year death rate after a hip fracture ranges from 10% to 66% depending on age and overall health, and survivors often face lasting disability. Hip fractures alone reduce healthy life expectancy by an average of 2.7%.
Surgery reduces this risk meaningfully. Patients who had parathyroid surgery had a 22% lower rate of any fracture and a 24% lower rate of hip fracture compared to those managed without surgery. The benefit grows over time: at two years, surgery reduced absolute fracture risk by 1.2%, but by ten years, that gap widened to 5.1%. For older adults weighing the risks of an operation, these numbers represent real years of mobility and independence.
The Kidney Connection
When hyperparathyroidism develops secondary to kidney disease, the two conditions feed each other. Developing secondary hyperparathyroidism was associated with a fivefold higher risk of kidney disease progression, defined as a doubling of creatinine levels or needing to start dialysis. The risk becomes especially apparent once kidney filtration drops below 45 mL/min, roughly stage 3b chronic kidney disease. As kidney function declines further, the incidence of secondary hyperparathyroidism rises sharply, from 57 new cases per 1,000 person-years in stage 3 to 230 per 1,000 in stage 5.
This feedback loop is why early treatment matters. Controlling parathyroid hormone levels helps slow kidney deterioration, and preserving kidney function helps keep parathyroid hormone in check. Breaking the cycle at any point improves the long-term outlook.
Factors That Shape Your Outlook
Several variables influence how hyperparathyroidism affects your lifespan. Your age at diagnosis matters: younger patients generally tolerate surgery well and have decades to benefit from it. The severity of calcium elevation plays a role, with higher levels carrying greater cardiovascular and kidney risk. Whether you have other conditions like diabetes, heart disease, or kidney impairment makes a significant difference, as hyperparathyroidism amplifies existing risks rather than creating them in isolation.
For secondary hyperparathyroidism, the level of parathyroid hormone itself predicts outcomes. Patients with levels above 585 pg/mL saw the greatest survival benefit from surgery (a 63% reduction in mortality risk), while those with lower levels showed no clear difference between surgical and medical management. In cases where medication alone brought hormone levels under adequate control, outcomes matched those of surgery.
The practical message is straightforward: primary hyperparathyroidism caught early and treated surgically has little to no impact on how long you live. Left untreated, it slowly damages your heart, bones, and kidneys in ways that can shorten your life over years or decades. Secondary hyperparathyroidism is a more serious condition tied to kidney failure, but even there, appropriate treatment can nearly double median survival time.